Biotech Values

[jq1234]

Sequencing: this goes both ways. If they don't cover Ztandi on Zytiga treated, they wouldn't cover Zytiga on Ztandi treated either. They might cover for sequencing of these two, but patients might not be on either of them long once they were treated with the other previously because it isn't effective at all. So it might depend on some type of sequencing data.

My point is it is difficult to say with any certainty what market share Ztandi gets relative to Zytiga, 50-50, 60-40?